van Grootheest Kees, de Jong-van den Berg Lolkje
The Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands.
Expert Opin Drug Saf. 2004 Jul;3(4):363-8. doi: 10.1517/14740338.3.4.363.
This review discusses the involvement of patients in the reporting of adverse drug reactions (ADRs). Patients benefit from drugs but also experience their adverse effects. Since concerns about the safety of drugs are also patients' concerns, the patient could also play a part in decreasing the risks of drug therapy. Patient interest in the safety aspects of drugs is evident. At an international level, the merits of patient reports are being considered. To date, the literature does not yet provide any actual results in relation to the detection of ADRs by patients. Different considerations regarding ADR reporting by patients are discussed. The authors conclude that we should positively value patients' involvement in drug therapy and their concern regarding possible adverse effects. As a consequence, patients' reports on ADRs should be accepted.
本综述讨论了患者在药物不良反应(ADR)报告中的参与情况。患者从药物中受益,但也会经历药物的不良反应。由于对药物安全性的关注也是患者的关注点,因此患者在降低药物治疗风险方面也可以发挥作用。患者对药物安全方面的兴趣是显而易见的。在国际层面,正在考虑患者报告的优点。迄今为止,文献尚未提供任何关于患者检测ADR的实际结果。本文讨论了关于患者报告ADR的不同考量因素。作者得出结论,我们应该积极重视患者在药物治疗中的参与以及他们对可能出现的不良反应的关注。因此,患者关于ADR的报告应该被接受。